Mitochondrial Metabolism: A New Dimension of Personalized Oncology
Open accessAbstract
Energy is needed by cancer cells to stay alive and communicate with their surroundings. The primary organelles for cellular metabolism and energy synthesis are mitochondria. Researchers recently proved that cancer cells can steal immune cells’ mitochondria using nanoscale tubes. This finding demonstrates the dependence of cancer cells on normal cells for their living and function. It also denotes the importance of mitochondria in cancer cells’ biology. Emerging evidence has demonstrated how mitochondria are essential for cancer cells to survive in the harsh tumor microenvironments, evade the immune system, obtain more aggressive features, and resist treatments. For instance, functional mitochondria can improve cancer resistance against radiotherapy by scavenging the released reactive oxygen species. Therefore, targeting mitochondria can potentially enhance oncological outcomes, according to this notion. The tumors’ responses to anticancer treatments vary, ranging from a complete response to even cancer progression during treatment. Therefore, personalized cancer treatment is of crucial importance. So far, personalized cancer treatment has been based on genomic analysis. Evidence shows that tumors with high mitochondrial content are more resistant to treatment. This paper illustrates how mitochondrial metabolism can participate in cancer resistance to chemotherapy, immunotherapy, and radiotherapy. Pretreatment evaluation of mitochondrial metabolism can provide additional information to genomic analysis and can help to improve personalized oncological treatments. This article outlines the importance of mitochondrial metabolism in cancer biology and personalized treatments.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Radiation therapy guided by a compound's affinity for specific targets is precise and effective in treating diseases, especially cancer.
“Guided by the compound's affinity for specific targets, radiation therapy becomes a precise and effective way to triumph over diseases [12].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [12]
The Introduction says radiotherapy aims to deliver the maximum dose to the affected area while minimizing harm to healthy tissue, and that personalized schedules aim to improve outcomes. It does not say that a compound’s affinity for specific targets guides radiation therapy; it describes tailoring schedules to tumor and patient characteristics instead. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 187 · Cited by 44
Research works printed but not linked: 2
- [51]Syljuåsen R.G. Cell cycle effects in radiation oncology Radiation Oncology Wentz F. Springer Berlin/Heidelberg, Germany 2019 1 8
- [105]Dai N. Groenendyk J. Michalak M. Binding Proteins|Ca2+ Binding/Buffering Proteins: ER Luminal Proteins☆ Encyclopedia of Biological Chemistry III 3rd ed. Jez J. Elsevier Oxford, UK 2021 534 546
- Authors
- Behnam, B., & Taghizadeh-Hesary, F.
- Affiliations
- National Sanitation Foundation International (US)
- ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran 1445613131, Iran
- Corresponding author
- Behnam, Babak
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-08-11
- Volume
- 15
- Issue
- 16
- Pages
- 4058
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10452105
- OpenAlex
- W4385760171
- Cited by
- 44
- References
- 187
- Citations by year
- 2026: 14 · 2025: 5 · 2024: 21 · 2023: 4
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mitochondrial metabolism, cancer cells, tumor microenvironment, immune evasion, treatment resistance, chemoresistance, immunotherapy resistance, radiotherapy resistance, reactive oxygen species, precision oncology, mitochondrial content
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
